




The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Strongbridge Biopharma plc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 124%, being 128% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	60,813
Cost of Goods Sold	0
Intangible Assets	42,411
Liabilities, Current	12,479
Liabilities, Non-Current	37,794
Other Assets	686
Other Compr. Net Income	0
Other Expenses	28,999
Other Liabilities	65,566
Other Net Income	-37,970
Other Revenues	7,046
Property and Equipment	15
Research and Development	17,268
Selling, General and Administrative Expense	36,292

Output Variable	Value in 1000 USD
Assets	103,925
Liabilities	115,839
Expenses	82,559
Revenues	7,046
Stockholders Equity	-11,914
Net Income	-113,483
Comprehensive Net Income	-113,483
BaseVar	173,670
ECR before LimitedLiability	-127%
Economic Capital Ratio	124%